Public dataset
Recorded source agreement and disagreement
Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.
- Public rows
- 1,681
- Generated
- Schema version
- source-consensus/2
Coverage
What this run contains
- Compared medicine fields
- 1,681
- Agree
- 1,282
- Differ
- 0
- Not comparable
- 12
- Insufficient context
- 387
- Fields represented
- 5
- bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
Method
How the rows were made
- Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
- One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
- Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
- not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
- The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
- Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
- documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.
Limits
Read these before using a row
- Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
- The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
- Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
- Only the recorded fields and source documents in this snapshot are compared.
- A source count is the number of retained source records in the row, not a count of independent experiments.
Provenance
Source examples
abacavir · bioavailability · agree
15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)The geometric mean absolute bioavailability of the tablet was 83%.
alemtuzumab · volumeOfDistribution · not_comparable
2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
abiraterone · halfLife · insufficient_context
31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| field | string | Recorded pharmacokinetic field being compared. |
| comparisonState | string | agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero. |
| comparisonReasons | string[] | Deterministic codes explaining the state. |
| documentsExamined | number | Recorded source documents considered for the field. |
| sourceCount | number | Recorded source readings represented. |
| agreementRate | number | Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability. |
| readings | consensus-reading[] | Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt. |
Reader
Search and filter the rows
Showing 1,461–1,470 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 1461
- Medicine slug
- tasimelteon
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 4
- Source count
- 4
- Agreement rate
- 1
- Recorded readings
38.3%
- Numeric value
- 38.3
- Unit
- %
- Source records
- 4
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 4 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:46b09064-a675-92d5-24a7-dac0410f77ae (opens source in a new tab)
Tasimelteon label
Version not recorded · Effective date not recorded
Absorption The absolute oral bioavailability is 38.3%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:99cb1928-e57d-4d04-87a1-38108780598a (opens source in a new tab)
Tasimelteon label
Version not recorded · Effective date not recorded
Absorption The absolute oral bioavailability is 38.3%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ca4a9b63-708e-49e9-8f9b-010625443b90 (opens source in a new tab)
Tasimelteon label
Version not recorded · Effective date not recorded
Absorption The absolute oral bioavailability is 38.3%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ce5a2fa3-ed54-422d-96c2-1821496eb32f (opens source in a new tab)
Tasimelteon label
Version not recorded · Effective date not recorded
Absorption The absolute oral bioavailability is 38.3%.
Projected row 1462
- Medicine slug
- tasimelteon
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 4
- Source count
- 4
- Agreement rate
- 1
- Recorded readings
1.3 ± 0.4 hours
- Numeric value
- 1.3
- Unit
- hours
- Source records
- 4
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 4 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:46b09064-a675-92d5-24a7-dac0410f77ae (opens source in a new tab)
Tasimelteon label
Version not recorded · Effective date not recorded
The observed mean elimination half-life for tasimelteon is 1.3 ± 0.4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:99cb1928-e57d-4d04-87a1-38108780598a (opens source in a new tab)
Tasimelteon label
Version not recorded · Effective date not recorded
The observed mean elimination half-life for tasimelteon is 1.3 ± 0.4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ca4a9b63-708e-49e9-8f9b-010625443b90 (opens source in a new tab)
Tasimelteon label
Version not recorded · Effective date not recorded
The observed mean elimination half-life for tasimelteon is 1.3 ± 0.4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ce5a2fa3-ed54-422d-96c2-1821496eb32f (opens source in a new tab)
Tasimelteon label
Version not recorded · Effective date not recorded
The observed mean elimination half-life for tasimelteon is 1.3 ± 0.4 hours.
Projected row 1463
- Medicine slug
- tasimelteon
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 4
- Source count
- 4
- Agreement rate
- 1
- Recorded readings
0.5 to 3 hours
- Numeric value
- 0.5
- Unit
- hours
- Source records
- 4
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 4 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:46b09064-a675-92d5-24a7-dac0410f77ae (opens source in a new tab)
Tasimelteon label
Version not recorded · Effective date not recorded
The peak concentration (T max ) of tasimelteon capsule occurred approximately 0.5 to 3 hours after fasted oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:99cb1928-e57d-4d04-87a1-38108780598a (opens source in a new tab)
Tasimelteon label
Version not recorded · Effective date not recorded
The peak concentration (T max ) of tasimelteon occurred approximately 0.5 to 3 hours after fasted oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ca4a9b63-708e-49e9-8f9b-010625443b90 (opens source in a new tab)
Tasimelteon label
Version not recorded · Effective date not recorded
The peak concentration (T max ) of tasimelteon capsule occurred approximately 0.5 to 3 hours after fasted oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ce5a2fa3-ed54-422d-96c2-1821496eb32f (opens source in a new tab)
Tasimelteon label
Version not recorded · Effective date not recorded
The peak concentration (T max ) of tasimelteon occurred approximately 0.5 to 3 hours after fasted oral administration.
Projected row 1464
- Medicine slug
- tazarotene
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 17
- Source count
- 14
- Agreement rate
- 1
- Recorded readings
18 hours
- Numeric value
- 18
- Unit
- hours
- Source records
- 14
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 14 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aa6fff2f-01c7-4669-be67-07cec82c768a (opens source in a new tab)
Tazarotene label
Version not recorded · Effective date not recorded
The half-life of tazarotenic acid was approximately 18 hours, following topical application of tazarotene to normal, acne or psoriatic skin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4e4e4b81-420e-4492-8a74-80b692a80057 (opens source in a new tab)
Tazarotene label
Version not recorded · Effective date not recorded
The half-life of tazarotenic acid was approximately 18 hours, following topical application of tazarotene to normal, acne or psoriatic skin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:34d79c31-1568-4797-a4f5-31200c7788db (opens source in a new tab)
Tazarotene label
Version not recorded · Effective date not recorded
The half-life of tazarotenic acid was approximately 18 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:478ff059-9d7b-438e-a64e-c853dfac2872 (opens source in a new tab)
Tazarotene label
Version not recorded · Effective date not recorded
The half-life of tazarotenic acid was approximately 18 hours, following topical application of tazarotene to normal, acne or psoriatic skin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0296f0e9-f940-45d9-987e-1ee26a7ca961 (opens source in a new tab)
Tazarotene label
Version not recorded · Effective date not recorded
The half-life of tazarotenic acid was approximately 18 hours, following topical application of tazarotene to normal, acne or psoriatic skin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:94749b8e-0d00-4257-a660-6d0fc8815fcf (opens source in a new tab)
Tazarotene label
Version not recorded · Effective date not recorded
The half-life of tazarotenic acid was approximately 18 hours, following topical application of tazarotene to normal, acne or psoriatic skin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:df5d65de-0693-4fd2-b335-f04ab1e201e7 (opens source in a new tab)
Tazarotene label
Version not recorded · Effective date not recorded
The half-life of tazarotenic acid was approximately 18 hours, following topical application of tazarotene to normal or psoriatic skin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:91264c0a-223c-47b7-b537-071944f25790 (opens source in a new tab)
Tazarotene label
Version not recorded · Effective date not recorded
The half-life of tazarotenic acid was approximately 18 hours, following topical application of tazarotene to normal or psoriatic skin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f1c98c4a-f101-4f3c-851a-39c827415c46 (opens source in a new tab)
Tazarotene label
Version not recorded · Effective date not recorded
The half-life of tazarotenic acid was approximately 18 hours, following topical application of tazarotene to normal, acne or psoriatic skin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:021744d1-a6d7-4ad6-99c2-7187c24e64c6 (opens source in a new tab)
Tazarotene label
Version not recorded · Effective date not recorded
The half-life of tazarotenic acid was approximately 18 hours, following topical application of tazarotene to normal, acne or psoriatic skin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ecd718fd-c06e-4b3a-8aca-fa51e7c51a66 (opens source in a new tab)
Tazarotene label
Version not recorded · Effective date not recorded
The half-life of tazarotenic acid was approximately 18 hours, following topical application of tazarotene to normal or psoriatic skin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1cf1faef-73b8-4ab2-a4c8-521f0bd3fc10 (opens source in a new tab)
Tazarotene label
Version not recorded · Effective date not recorded
The half-life of tazarotenic acid was approximately 18 hours, following topical application of tazarotene to normal, acne or psoriatic skin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ffd11dee-4266-4201-9573-1e82c2d30a63 (opens source in a new tab)
Tazarotene label
Version not recorded · Effective date not recorded
The half-life of tazarotenic acid was approximately 18 hours, following topical application of tazarotene to normal, acne or psoriatic skin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fa5caf83-29d5-8229-b125-d7736928f132 (opens source in a new tab)
Tazarotene label
Version not recorded · Effective date not recorded
The half-life of tazarotenic acid was approximately 18 hours, following topical application of tazarotene to normal, acne or psoriatic skin.
Projected row 1465
- Medicine slug
- tazarotene
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 17
- Source count
- 17
- Agreement rate
- 1
- Recorded readings
99%
- Numeric value
- 99
- Unit
- %
- Source records
- 17
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 17 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aa6fff2f-01c7-4669-be67-07cec82c768a (opens source in a new tab)
Tazarotene label
Version not recorded · Effective date not recorded
Tazarotenic acid was highly bound to plasma proteins (greater than 99%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4e4e4b81-420e-4492-8a74-80b692a80057 (opens source in a new tab)
Tazarotene label
Version not recorded · Effective date not recorded
Tazarotenic acid was highly bound to plasma proteins (greater than 99%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d941ff25-c221-4a55-8012-0dcf3bbcbbd1 (opens source in a new tab)
Tazarotene label
Version not recorded · Effective date not recorded
Tazarotenic acid is highly bound to plasma proteins (greater than 99%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:34d79c31-1568-4797-a4f5-31200c7788db (opens source in a new tab)
Tazarotene label
Version not recorded · Effective date not recorded
Tazarotenic acid was highly bound to plasma proteins (greater than 99%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:478ff059-9d7b-438e-a64e-c853dfac2872 (opens source in a new tab)
Tazarotene label
Version not recorded · Effective date not recorded
Tazarotenic acid was highly bound to plasma proteins (greater than 99%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0296f0e9-f940-45d9-987e-1ee26a7ca961 (opens source in a new tab)
Tazarotene label
Version not recorded · Effective date not recorded
Tazarotenic acid was highly bound to plasma proteins (greater than 99%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:94749b8e-0d00-4257-a660-6d0fc8815fcf (opens source in a new tab)
Tazarotene label
Version not recorded · Effective date not recorded
Tazarotenic acid was highly bound to plasma proteins (greater than 99%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:df5d65de-0693-4fd2-b335-f04ab1e201e7 (opens source in a new tab)
Tazarotene label
Version not recorded · Effective date not recorded
Tazarotenic acid was highly bound to plasma proteins (greater than 99%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:91264c0a-223c-47b7-b537-071944f25790 (opens source in a new tab)
Tazarotene label
Version not recorded · Effective date not recorded
Tazarotenic acid was highly bound to plasma proteins (greater than 99%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0e337598-f589-483f-a2ae-be7c319d7454 (opens source in a new tab)
Tazarotene label
Version not recorded · Effective date not recorded
Tazarotenic acid was highly bound to plasma proteins (greater than 99%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f1c98c4a-f101-4f3c-851a-39c827415c46 (opens source in a new tab)
Tazarotene label
Version not recorded · Effective date not recorded
Tazarotenic acid was highly bound to plasma proteins (greater than 99%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ae0afed7-1d60-45fd-a08b-8db094618521 (opens source in a new tab)
Tazarotene label
Version not recorded · Effective date not recorded
Tazarotenic acid was highly bound to plasma proteins (greater than 99%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:021744d1-a6d7-4ad6-99c2-7187c24e64c6 (opens source in a new tab)
Tazarotene label
Version not recorded · Effective date not recorded
Tazarotenic acid was highly bound to plasma proteins (greater than 99%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ecd718fd-c06e-4b3a-8aca-fa51e7c51a66 (opens source in a new tab)
Tazarotene label
Version not recorded · Effective date not recorded
Tazarotenic acid was highly bound to plasma proteins (greater than 99%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1cf1faef-73b8-4ab2-a4c8-521f0bd3fc10 (opens source in a new tab)
Tazarotene label
Version not recorded · Effective date not recorded
Tazarotenic acid was highly bound to plasma proteins (greater than 99%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ffd11dee-4266-4201-9573-1e82c2d30a63 (opens source in a new tab)
Tazarotene label
Version not recorded · Effective date not recorded
Tazarotenic acid was highly bound to plasma proteins (greater than 99%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fa5caf83-29d5-8229-b125-d7736928f132 (opens source in a new tab)
Tazarotene label
Version not recorded · Effective date not recorded
Tazarotenic acid was highly bound to plasma proteins (greater than 99%).
Projected row 1466
- Medicine slug
- tazarotene
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 17
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
6 hours
- Numeric value
- 6
- Unit
- hours
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0e337598-f589-483f-a2ae-be7c319d7454 (opens source in a new tab)
Tazarotene label
Version not recorded · Effective date not recorded
The median T max was 6 hours (range: 4.4 to 12 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ae0afed7-1d60-45fd-a08b-8db094618521 (opens source in a new tab)
Tazarotene label
Version not recorded · Effective date not recorded
The median T max was 6 hours (range: 4.4 to 12 hours).
Projected row 1467
- Medicine slug
- technetium-tc-99m-sestamibi
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 2
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
3 hours
- Numeric value
- 3
- Unit
- hours
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4110d0f4-3bcf-4688-a39f-42a81064c796 (opens source in a new tab)
Technetium Tc-99m Sestamibi label
Version not recorded · Effective date not recorded
The effective half-life of clearance (which includes both the biological half-life and radionuclide decay) for the heart is approximately 3 hours, and for the liver is approximately 30 minutes, after a rest or exercise injection.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:07c893fc-cfba-1d98-0232-6448463afb87 (opens source in a new tab)
Technetium Tc-99m Sestamibi label
Version not recorded · Effective date not recorded
The effective half-life of clearance (which includes both the biological half-life and radionuclide decay) for the heart is approximately 3 hours, and for the liver is approximately 30 minutes, after a rest or exercise injection.
Projected row 1468
- Medicine slug
- telmisartan
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 41
- Source count
- 41
- Agreement rate
- 1
- Recorded readings
42%
- Numeric value
- 42
- Unit
- %
- Source records
- 41
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 41 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a075633a-2a2a-4e88-8ede-b49a3920a16c (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
At 40 mg and 160 mg, the bioavailability was 42% and 58%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf8e95fa-d181-4b46-8609-497e14a73dc1 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
At 40 mg and 160 mg the bioavailability was 42% and 58%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57da6ef2-2e86-4e4d-90df-73a2a8cf97f6 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
At 40 mg and 160 mg, the bioavailability was 42% and 58%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:509cd338-24db-41d1-a115-9dc999170717 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
At 40 mg and 160 mg, the bioavailability was 42% and 58%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e1a907a7-fad9-a860-8639-4c6136c85734 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
At 40 and 160 mg the bioavailability was 42% and 58%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9c22a318-d1f2-4788-9331-66fed71ebf38 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
At 40 mg and 160 mg, the bioavailability was 42% and 58%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:830741dd-3f3c-4f8e-88c6-dc112166f477 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
At 40 and 160 mg the bioavailability was 42% and 58%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:56a72ddf-c2a2-45ce-91b1-1fcfbff52c10 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
At 40 and 160 mg the bioavailability was 42% and 58%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b4ae8694-2af4-4acb-8634-b40c1cb6fb41 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
At 40 mg and 160 mg, the bioavailability was 42% and 58%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:32489e86-0432-4d74-92f6-15e7450f52fa (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
At 40 and 160 mg the bioavailability was 42% and 58%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:beaaf383-730f-4411-b5e7-15c32b53a338 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
At 40 mg and 160 mg the bioavailability was 42% and 58%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eaed12cd-5bfe-4c98-9afc-025ed86a294f (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
At 40 mg and 160 mg, the bioavailability was 42% and 58%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:09d31eee-cd22-4918-a889-3eb4d2969525 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
At 40 and 160 mg the bioavailability was 42% and 58%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:77442f0b-b522-4b19-ac1f-f0ce8576f0be (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
At 40 mg and 160 mg, the bioavailability was 42% and 58%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f13e0919-5ee2-4855-b7c8-c8ab423769dd (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
At 40 mg and 160 mg, the bioavailability was 42% and 58%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c3658bc8-1524-43db-930e-66f9ac01b808 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
At 40 mg and 160 mg, the bioavailability was 42% and 58%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e61c209a-4fc3-4f5c-b526-6412f0b8897c (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
At 40 mg and 160 mg, the bioavailability was 42% and 58%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:44e810d4-cf04-41d3-bdf8-0681210a669f (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
At 40 and 160 mg the bioavailability was 42% and 58%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:671d5a85-4146-43b4-9d7d-ca53268eb2a6 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
At 40 and 160 mg the bioavailability was 42% and 58%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4be6575f-ea8d-4cd8-a49d-3d1c93f2621a (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
At 40 and 160 mg the bioavailability was 42% and 58%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3f021f06-99df-48d1-e063-6394a90a8d0f (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
At 40 mg and 160 mg, the bioavailability was 42% and 58%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f6da5155-9c26-46bb-bc0f-ece4ea21405f (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
At 40 and 160 mg the bioavailability was 42% and 58%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:91215664-6e19-4e04-9ae7-ab5664799426 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
At 40 mg and 160 mg the bioavailability was 42% and 58%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d45da80a-58c3-4461-adf6-a85531c09eb8 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
At 40 mg and 160 mg, the bioavailability was 42% and 58%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a5ded796-3555-4476-8b37-0cdc88d7594a (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
At 40 and 160 mg the bioavailability was 42% and 58%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:353fcb30-2fa7-4ff1-8a18-26f3ec279d00 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
At 40 mg and 160 mg the bioavailability was 42% and 58%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fef6532d-438a-435e-a61f-216dd8551339 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
At 40 mg and 160 mg, the bioavailability was 42% and 58%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:963e9245-ec7a-4bf6-9fc0-80f54e3657f0 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
At 40 and 160 mg the bioavailability was 42% and 58%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c55e4fe1-f04d-4995-a706-9f432fde57e4 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
At 40 mg and 160 mg the bioavailability was 42% and 58%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5743c58e-deab-ac93-e063-6294a90ac1eb (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
At 40 mg and 160 mg, the bioavailability was 42% and 58%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e2deff49-b75e-4aaa-8114-d5ea1e3a94a5 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
At 40 mg and 160 mg, the bioavailability was 42% and 58%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dd2b0604-f887-40d9-9109-dafcc9987e4e (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
At 40 and 160 mg the bioavailability was 42% and 58%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a020e2a7-d1e7-8ae0-e053-2995a90abad3 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
At 40 and 160 mg the bioavailability was 42% and 58%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:71902893-55da-4286-8b25-b528641489ef (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
At 40 and 160 mg the bioavailability was 42% and 58%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:593a53a4-91bc-4e4a-aeff-08fc2efe3dd4 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
At 40 and 160 mg the bioavailability was 42% and 58%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:20a60231-64f0-4751-aa81-6c0e64334179 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
At 40 mg and 160 mg, the bioavailability was 42% and 58%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c6eb489d-2946-4c14-839f-d4af761ead31 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
At 40 mg and 160 mg the bioavailability was 42% and 58%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c62d424c-7630-413c-be2c-3932831c3f1d (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
At 40 mg and 160 mg, the bioavailability was 42% and 58%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:29bddc43-2809-4e1f-ae35-2865e15e9bb6 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
At 40 and 160 mg the bioavailability was 42% and 58%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf2dca37-ce9c-40e4-8ad6-b8186aa7fed1 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
At 40 mg and 160 mg, the bioavailability was 42% and 58%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3ff464e6-7a36-4544-a06f-7848414f77fc (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
At 40 mg and 160 mg, the bioavailability was 42% and 58%, respectively.
Projected row 1469
- Medicine slug
- telmisartan
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 41
- Source count
- 38
- Agreement rate
- 1
- Recorded readings
24 hours
- Numeric value
- 24
- Unit
- hours
- Source records
- 38
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 38 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a075633a-2a2a-4e88-8ede-b49a3920a16c (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Telmisartan shows bi-exponential decay kinetics with a terminal elimination half-life of approximately 24 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf8e95fa-d181-4b46-8609-497e14a73dc1 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Telmisartan shows bi-exponential decay kinetics with a terminal elimination half-life of approximately 24 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57da6ef2-2e86-4e4d-90df-73a2a8cf97f6 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Telmisartan shows bi-exponential decay kinetics with a terminal elimination half-life of approximately 24 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:509cd338-24db-41d1-a115-9dc999170717 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Telmisartan shows bi-exponential decay kinetics with a terminal elimination half-life of approximately 24 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e1a907a7-fad9-a860-8639-4c6136c85734 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Telmisartan shows bi-exponential decay kinetics with a terminal elimination half-life of approximately 24 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9c22a318-d1f2-4788-9331-66fed71ebf38 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Telmisartan shows bi-exponential decay kinetics with a terminal elimination half-life of approximately 24 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:830741dd-3f3c-4f8e-88c6-dc112166f477 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Telmisartan shows bi-exponential decay kinetics with a terminal elimination half-life of approximately 24 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:56a72ddf-c2a2-45ce-91b1-1fcfbff52c10 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Telmisartan shows bi-exponential decay kinetics with a terminal elimination half-life of approximately 24 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b4ae8694-2af4-4acb-8634-b40c1cb6fb41 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Telmisartan shows bi-exponential decay kinetics with a terminal elimination half-life of approximately 24 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:32489e86-0432-4d74-92f6-15e7450f52fa (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Telmisartan shows bi-exponential decay kinetics with a terminal elimination half-life of approximately 24 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:beaaf383-730f-4411-b5e7-15c32b53a338 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Telmisartan shows bi-exponential decay kinetics with a terminal elimination half-life of approximately 24 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eaed12cd-5bfe-4c98-9afc-025ed86a294f (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Telmisartan shows bi-exponential decay kinetics with a terminal elimination half-life of approximately 24 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:09d31eee-cd22-4918-a889-3eb4d2969525 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Telmisartan shows bi-exponential decay kinetics with a terminal elimination half-life of approximately 24 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:77442f0b-b522-4b19-ac1f-f0ce8576f0be (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Telmisartan shows bi-exponential decay kinetics with a terminal elimination half-life of approximately 24 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f13e0919-5ee2-4855-b7c8-c8ab423769dd (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Telmisartan shows bi-exponential decay kinetics with a terminal elimination half-life of approximately 24 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c3658bc8-1524-43db-930e-66f9ac01b808 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Telmisartan shows bi-exponential decay kinetics with a terminal elimination half-life of approximately 24 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:44e810d4-cf04-41d3-bdf8-0681210a669f (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Telmisartan shows bi-exponential decay kinetics with a terminal elimination half-life of approximately 24 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4be6575f-ea8d-4cd8-a49d-3d1c93f2621a (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Telmisartan shows bi-exponential decay kinetics with a terminal elimination half-life of approximately 24 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3f021f06-99df-48d1-e063-6394a90a8d0f (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Telmisartan shows bi-exponential decay kinetics with a terminal elimination half-life of approximately 24 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f6da5155-9c26-46bb-bc0f-ece4ea21405f (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Telmisartan shows bi-exponential decay kinetics with a terminal elimination half-life of approximately 24 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:91215664-6e19-4e04-9ae7-ab5664799426 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Telmisartan shows bi-exponential decay kinetics with a terminal elimination half-life of approximately 24 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d45da80a-58c3-4461-adf6-a85531c09eb8 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Telmisartan shows bi-exponential decay kinetics with a terminal elimination half-life of approximately 24 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a5ded796-3555-4476-8b37-0cdc88d7594a (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Telmisartan shows bi-exponential decay kinetics with a terminal elimination half-life of approximately 24 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:353fcb30-2fa7-4ff1-8a18-26f3ec279d00 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Telmisartan shows bi-exponential decay kinetics with a terminal elimination half-life of approximately 24 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fef6532d-438a-435e-a61f-216dd8551339 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Telmisartan shows bi-exponential decay kinetics with a terminal elimination half-life of approximately 24 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:963e9245-ec7a-4bf6-9fc0-80f54e3657f0 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Telmisartan shows bi-exponential decay kinetics with a terminal elimination half-life of approximately 24 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c55e4fe1-f04d-4995-a706-9f432fde57e4 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Telmisartan shows bi-exponential decay kinetics with a terminal elimination half-life of approximately 24 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5743c58e-deab-ac93-e063-6294a90ac1eb (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Telmisartan shows bi-exponential decay kinetics with a terminal elimination half-life of approximately 24 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e2deff49-b75e-4aaa-8114-d5ea1e3a94a5 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Telmisartan shows bi-exponential decay kinetics with a terminal elimination half-life of approximately 24 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dd2b0604-f887-40d9-9109-dafcc9987e4e (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Telmisartan shows bi-exponential decay kinetics with a terminal elimination half-life of approximately 24 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a020e2a7-d1e7-8ae0-e053-2995a90abad3 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Telmisartan shows bi-exponential decay kinetics with a terminal elimination half-life of approximately 24 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:71902893-55da-4286-8b25-b528641489ef (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Telmisartan shows bi-exponential decay kinetics with a terminal elimination half-life of approximately 24 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:20a60231-64f0-4751-aa81-6c0e64334179 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Telmisartan shows bi-exponential decay kinetics with a terminal elimination half-life of approximately 24 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c6eb489d-2946-4c14-839f-d4af761ead31 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Telmisartan shows bi-exponential decay kinetics with a terminal elimination half-life of approximately 24 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c62d424c-7630-413c-be2c-3932831c3f1d (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Telmisartan shows bi-exponential decay kinetics with a terminal elimination half-life of approximately 24 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:29bddc43-2809-4e1f-ae35-2865e15e9bb6 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Telmisartan shows bi-exponential decay kinetics with a terminal elimination half-life of approximately 24 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf2dca37-ce9c-40e4-8ad6-b8186aa7fed1 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Telmisartan shows bi-exponential decay kinetics with a terminal elimination half-life of approximately 24 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3ff464e6-7a36-4544-a06f-7848414f77fc (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Telmisartan shows bi-exponential decay kinetics with a terminal elimination half-life of approximately 24 hours.
Projected row 1470
- Medicine slug
- telmisartan
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 41
- Source count
- 41
- Agreement rate
- 1
- Recorded readings
99.5%
- Numeric value
- 99.5
- Unit
- %
- Source records
- 41
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 41 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a075633a-2a2a-4e88-8ede-b49a3920a16c (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Distribution Telmisartan is highly bound to plasma proteins (>99.5%), mainly albumin and α 1 -acid glycoprotein.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf8e95fa-d181-4b46-8609-497e14a73dc1 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Distribution Telmisartan is highly bound to plasma proteins (>99.5%), mainly albumin and α 1 - acid glycoprotein.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57da6ef2-2e86-4e4d-90df-73a2a8cf97f6 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Distribution Telmisartan is highly bound to plasma proteins (>99.5%), mainly albumin and α 1 - acid glycoprotein.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:509cd338-24db-41d1-a115-9dc999170717 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Distribution Telmisartan is highly bound to plasma proteins (> 99.5%), mainly albumin and α 1 -acid glycoprotein.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e1a907a7-fad9-a860-8639-4c6136c85734 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Distribution Telmisartan is highly bound to plasma proteins (>99.5%), mainly albumin and α 1 - acid glycoprotein.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9c22a318-d1f2-4788-9331-66fed71ebf38 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Distribution Telmisartan is highly bound to plasma proteins (>99.5%), mainly albumin and α 1 - acid glycoprotein.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:830741dd-3f3c-4f8e-88c6-dc112166f477 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Distribution Telmisartan is highly bound to plasma proteins (>99.5%), mainly albumin and α 1 - acid glycoprotein.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:56a72ddf-c2a2-45ce-91b1-1fcfbff52c10 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Distribution Telmisartan is highly bound to plasma proteins (>99.5%), mainly albumin and α 1 – acid glycoprotein.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b4ae8694-2af4-4acb-8634-b40c1cb6fb41 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Distribution Telmisartan is highly bound to plasma proteins (>99.5%), mainly albumin and α 1 -acid glycoprotein.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:32489e86-0432-4d74-92f6-15e7450f52fa (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Distribution Telmisartan is highly bound to plasma proteins (>99.5%), mainly albumin and α 1 – acid glycoprotein.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:beaaf383-730f-4411-b5e7-15c32b53a338 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Distribution Telmisartan is highly bound to plasma proteins (> 99.5%), mainly albumin and α1 - acid glycoprotein.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eaed12cd-5bfe-4c98-9afc-025ed86a294f (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Distribution Telmisartan is highly bound to plasma proteins (> 99.5%), mainly albumin and α 1 -acid glycoprotein.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:09d31eee-cd22-4918-a889-3eb4d2969525 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Distribution Telmisartan is highly bound to plasma proteins (>99.5%), mainly albumin and α 1 – acid glycoprotein.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:77442f0b-b522-4b19-ac1f-f0ce8576f0be (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Distribution Telmisartan is highly bound to plasma proteins (>99.5%), mainly albumin and α 1 - acid glycoprotein.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f13e0919-5ee2-4855-b7c8-c8ab423769dd (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Distribution Telmisartan is highly bound to plasma proteins (>99.5%), mainly albumin and α 1 -acid glycoprotein.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c3658bc8-1524-43db-930e-66f9ac01b808 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Distribution Telmisartan is highly bound to plasma proteins (> 99.5%), mainly albumin and α 1 -acid glycoprotein.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e61c209a-4fc3-4f5c-b526-6412f0b8897c (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Distribution Telmisartan is highly bound to plasma proteins (> 99.5%), mainly albumin and α 1 - acid glycoprotein.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:44e810d4-cf04-41d3-bdf8-0681210a669f (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Distribution Telmisartan is highly bound to plasma proteins (>99.5%), mainly albumin and α 1 – acid glycoprotein.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:671d5a85-4146-43b4-9d7d-ca53268eb2a6 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Distribution Telmisartan is highly bound to plasma proteins (>99.5%), mainly albumin and α 1 - acid glycoprotein.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4be6575f-ea8d-4cd8-a49d-3d1c93f2621a (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Distribution Telmisartan is highly bound to plasma proteins (>99.5%), mainly albumin and α 1 -acid glycoprotein.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3f021f06-99df-48d1-e063-6394a90a8d0f (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Distribution Telmisartan is highly bound to plasma proteins (>99.5%), mainly albumin and α 1 - acid glycoprotein.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f6da5155-9c26-46bb-bc0f-ece4ea21405f (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Distribution Telmisartan is highly bound to plasma proteins (>99.5%), mainly albumin and α 1 – acid glycoprotein.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:91215664-6e19-4e04-9ae7-ab5664799426 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Distribution Telmisartan is highly bound to plasma proteins (>99.5%), mainly albumin and α 1 - acid glycoprotein.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d45da80a-58c3-4461-adf6-a85531c09eb8 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Distribution Telmisartan is highly bound to plasma proteins (>99.5%), mainly albumin and α 1 - acid glycoprotein.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a5ded796-3555-4476-8b37-0cdc88d7594a (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Distribution Telmisartan is highly bound to plasma proteins (>99.5%), mainly albumin and α 1 - acid glycoprotein.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:353fcb30-2fa7-4ff1-8a18-26f3ec279d00 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Distribution Telmisartan is highly bound to plasma proteins (>99.5%), mainly albumin and α 1 -acid glycoprotein.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fef6532d-438a-435e-a61f-216dd8551339 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Distribution Telmisartan is highly bound to plasma proteins (>99.5%), mainly albumin and α 1 - acid glycoprotein.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:963e9245-ec7a-4bf6-9fc0-80f54e3657f0 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Distribution Telmisartan is highly bound to plasma proteins (>99.5%), mainly albumin and α 1 – acid glycoprotein.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c55e4fe1-f04d-4995-a706-9f432fde57e4 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Distribution Telmisartan is highly bound to plasma proteins (>99.5%), mainly albumin and α 1 - acid glycoprotein.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5743c58e-deab-ac93-e063-6294a90ac1eb (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Distribution Telmisartan is highly bound to plasma proteins (>99.5%), mainly albumin and α 1 - acid glycoprotein.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e2deff49-b75e-4aaa-8114-d5ea1e3a94a5 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Distribution Telmisartan is highly bound to plasma proteins (>99.5%), mainly albumin and α 1 -acid glycoprotein.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dd2b0604-f887-40d9-9109-dafcc9987e4e (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Distribution Telmisartan is highly bound to plasma proteins (>99.5%), mainly albumin and α 1 – acid glycoprotein.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a020e2a7-d1e7-8ae0-e053-2995a90abad3 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Distribution Telmisartan is highly bound to plasma proteins (>99.5%), mainly albumin and α 1 -acid glycoprotein.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:71902893-55da-4286-8b25-b528641489ef (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Distribution Telmisartan is highly bound to plasma proteins (>99.5%), mainly albumin and α 1 - acid glycoprotein.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:593a53a4-91bc-4e4a-aeff-08fc2efe3dd4 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Distribution Telmisartan is highly bound to plasma proteins (>99.5%), mainly albumin and α 1 – acid glycoprotein.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:20a60231-64f0-4751-aa81-6c0e64334179 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Distribution Telmisartan is highly bound to plasma proteins (> 99.5%), mainly albumin and α 1 - acid glycoprotein.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c6eb489d-2946-4c14-839f-d4af761ead31 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Distribution Telmisartan is highly bound to plasma proteins (>99.5%), mainly albumin and α 1 - acid glycoprotein.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c62d424c-7630-413c-be2c-3932831c3f1d (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Distribution Telmisartan is highly bound to plasma proteins (>99.5%), mainly albumin and α 1 -acid glycoprotein.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:29bddc43-2809-4e1f-ae35-2865e15e9bb6 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Distribution Telmisartan is highly bound to plasma proteins (>99.5%), mainly albumin and α 1 – acid glycoprotein.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf2dca37-ce9c-40e4-8ad6-b8186aa7fed1 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Distribution Telmisartan is highly bound to plasma proteins (> 99.5%), mainly albumin and α 1 - acid glycoprotein.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3ff464e6-7a36-4544-a06f-7848414f77fc (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
Distribution Telmisartan is highly bound to plasma proteins (>99.5%), mainly albumin and α 1 -acid glycoprotein.
Access
Query or download the projection
GET /api/datasets/source-consensus?limit=10&offset=1460Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- state
- Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
- field
- Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.